Aripiprazole + Bupropion for Depression

(BAARD Trial)

This trial tests new methods for selecting medications for older adults with depression unresponsive to standard treatments. It aims to determine if a predictive model, called BAARD, can more effectively reduce depression symptoms compared to random selection. Participants will take either aripiprazole (an antipsychotic) or bupropion (an antidepressant) alongside their current antidepressant for 10 weeks. Individuals aged 60 and over, who have tried at least two antidepressants without success, may qualify for this study. Regular follow-ups will monitor progress and ensure safety. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to benefit from a more targeted approach to depression treatment.

Research has shown that both aripiprazole and bupropion are generally safe and effective for treating depression. Aripiprazole, often used for depression and other mood disorders, has undergone extensive study. While most people find it safe, some may experience side effects like weight gain or restlessness.

Bupropion is another medication commonly used for depression, known for causing fewer sexual side effects compared to some other antidepressants. However, it can cause trouble sleeping or a dry mouth in some individuals. Both medications have FDA approval for treating depression and other conditions, indicating a good safety record when used as directed.

Researchers are excited about the trial of aripiprazole and bupropion for depression because it uses a smart, tailored approach to treatment selection. Unlike standard treatments that often involve trial and error with medications like SSRIs or SNRIs, this trial employs the BAARD predictive model to analyze individual data and suggest the best medication, whether aripiprazole or bupropion, for each participant. This personalized method could lead to faster, more effective relief for patients by matching them with the most suitable treatment from the start, rather than relying on random assignment or traditional methods.

Research has shown that both aripiprazole and bupropion can aid individuals with depression unresponsive to other treatments. In this trial, participants will receive either aripiprazole or bupropion. Specifically, adding aripiprazole to regular antidepressants has helped older adults by balancing dopamine, which can enhance mood. Many studies have proven that bupropion lowers depression levels, functioning like other antidepressants but often with fewer side effects. Both medications have strong evidence supporting their ability to improve depression symptoms, making them promising options for those who haven't found relief from other treatments.⁶⁷⁸⁹¹⁰